Clinical Trials List
Protocol Number2215-CL-0104
NCT Number(ClinicalTrials.gov Identfier)NCT02310321
Completed
2019-11-27 - 2022-03-31
Phase I/II
Not yet recruiting3
Recruiting1
A Phase 1/2 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
-
Trial Applicant
PPD DEVELOPMENT (HK) LIMITED
-
Sponsor
Astellas Pharma Inc
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Tzu-Ting Chen Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- Ming-Hung Tsai Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Tung-Liang Lin Division of Hematology & Oncology
- Ming-Chung Kao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Jeng-Shiun Du Division of Hematology & Oncology
- Hui-Ching Wang Division of Hematology & Oncology
- Yi-Chang Liu Division of Hematology & Oncology
- Shih-Feng Cho Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Ya-Ting Hsu Division of Hematology & Oncology
- Ya-Ping Chen Division of Hematology & Oncology
- Sin-Syue Li Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Acute Myeloid Leukemia / FLT3-mutated Acute Myeloid Leukemia
Objectives
The purpose of phase 1 part in this study is to determine the maximum tolerated dose (MTD) and/or recommended expansion dose (RED) of ASP2215 concomitant with cytarabine/idarubicin as induction chemotherapy based on the status of the onset of dose-limiting toxicity (DLT) in newly diagnosed Acute Myeloid Leukemia (AML) subjects. Phase 1 part will also evaluate safety and tolerability and characterize the pharmacokinetic (PK) parameters of ASP2215 concomitant with induction and consolidation chemotherapy as well as evaluate the PK parameters of cytarabine concomitant with ASP2215.
The purpose of phase 2 part is to evaluate efficacy of ASP2215 in combination with induction therapy. Phase 2 cohort will also evaluate safety and characterize the PK parameters of ASP2215 in combination with induction and consolidation therapy followed by maintenance therapy in newly diagnosed FLT3-mutated AML subjects.
Test Drug
Gilteritinib (ASP2215)
Active Ingredient
Gilteritinib(ASP2215)
Dosage Form
Tablet
Dosage
40mg
Endpoints
Primary Outcome Measures:
1. Phase 1 part: Maximum tolerated dose (MTD).
2. Phase 1 part: Recommended expansion dose (RED).
3. Phase 1 part: Number of participants with dose limiting toxicities (DLTs).
4. Phase 1 part: Number of participants with Adverse Events (AEs).
5. Phase 1 part: Number of participants with laboratory value abnormalities and/or AEs.
6. Phase 1 part: Number of participants with vital sign abnormalities and/or AEs.
7. Phase 2 part: Complete remission (CR) rate after induction therapy period.
Secondary Outcome Measures:
1. Phase 1 part: Pharmacokinetics of ASP2215 in plasma: Maximum concentration (Cmax).
2. Phase 1 part: PK of ASP2215 in plasma: Time to attain Cmax (tmax).
3. Phase 1 part: PK of ASP2215 in plasma: Area under plasma concentration-time curve from time 0 to 24 (AUC24).
4. Phase 1 part: PK of ASP2215 in plasma: Oral clearance (CL/F).
5. Phase 1 part: PK of ASP2215 in plasma: AUC from time 0 to last measurable concentration (AUClast).
6. Phase 1 part: PK of ASP2215 in plasma: Apparent terminal elimination half-life (t1/2).
7. Phase 1 part: PK of ASP2215 in plasma: Apparent Volume of Distribution During the Terminal Elimination Phase after Oral Dosing (Vz/F).
8. Phase 1 part: PK of ASP2215 in plasma: Plasma trough concentration (Ctrough).
9. Phase 1 part: PK of cytarabine in plasma: Ctrough.
10. Phase 2 part: PK of ASP2215 in plasma: Concentration.
11. Phase 2 part: Duration of overall survival (OS).
12. Phase 2 part: Duration of event free survival (EFS).
13. Phase 2 part: Duration of relapse free survival (RFS).
14. Phase 2 part: CR rate after each treatment therapy.
15. Phase 2 part: CR rate without minimal residual disease (MRD) after each treatment therapy.
16. Phase 2 part: CR with partial hematological recovery (CRh) rate after each treatment therapy.
17. Phase 2 part: Composite CR (CRc) rate after each treatment therapy.
18. Phase 2 part: Duration of CR.
19. Phase 2 part: Duration of CRh.
20. Phase 2 part: Duration of CRc.
21. Phase 2 part: Number of participants with AEs.
22. Phase 2 part: Number of participants with laboratory value abnormalities and/or AEs.
23. Phase 2 part: Number of participants with vital sign abnormalities and/or AEs.
24. Phase 2 part: Number of participants with 12- ECG abnormalities and/or AEs.
1. Phase 1 part: Maximum tolerated dose (MTD).
2. Phase 1 part: Recommended expansion dose (RED).
3. Phase 1 part: Number of participants with dose limiting toxicities (DLTs).
4. Phase 1 part: Number of participants with Adverse Events (AEs).
5. Phase 1 part: Number of participants with laboratory value abnormalities and/or AEs.
6. Phase 1 part: Number of participants with vital sign abnormalities and/or AEs.
7. Phase 2 part: Complete remission (CR) rate after induction therapy period.
Secondary Outcome Measures:
1. Phase 1 part: Pharmacokinetics of ASP2215 in plasma: Maximum concentration (Cmax).
2. Phase 1 part: PK of ASP2215 in plasma: Time to attain Cmax (tmax).
3. Phase 1 part: PK of ASP2215 in plasma: Area under plasma concentration-time curve from time 0 to 24 (AUC24).
4. Phase 1 part: PK of ASP2215 in plasma: Oral clearance (CL/F).
5. Phase 1 part: PK of ASP2215 in plasma: AUC from time 0 to last measurable concentration (AUClast).
6. Phase 1 part: PK of ASP2215 in plasma: Apparent terminal elimination half-life (t1/2).
7. Phase 1 part: PK of ASP2215 in plasma: Apparent Volume of Distribution During the Terminal Elimination Phase after Oral Dosing (Vz/F).
8. Phase 1 part: PK of ASP2215 in plasma: Plasma trough concentration (Ctrough).
9. Phase 1 part: PK of cytarabine in plasma: Ctrough.
10. Phase 2 part: PK of ASP2215 in plasma: Concentration.
11. Phase 2 part: Duration of overall survival (OS).
12. Phase 2 part: Duration of event free survival (EFS).
13. Phase 2 part: Duration of relapse free survival (RFS).
14. Phase 2 part: CR rate after each treatment therapy.
15. Phase 2 part: CR rate without minimal residual disease (MRD) after each treatment therapy.
16. Phase 2 part: CR with partial hematological recovery (CRh) rate after each treatment therapy.
17. Phase 2 part: Composite CR (CRc) rate after each treatment therapy.
18. Phase 2 part: Duration of CR.
19. Phase 2 part: Duration of CRh.
20. Phase 2 part: Duration of CRc.
21. Phase 2 part: Number of participants with AEs.
22. Phase 2 part: Number of participants with laboratory value abnormalities and/or AEs.
23. Phase 2 part: Number of participants with vital sign abnormalities and/or AEs.
24. Phase 2 part: Number of participants with 12- ECG abnormalities and/or AEs.
Inclution Criteria
[Phase 1 part]
1. Subject is defined as having previously untreated de novo AML according to the World Health Organization (WHO) criteria (2008) within 28 days prior to study enrollment.
2. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
3. Subject must meet all of the following criteria in the laboratory test at screening:
(1) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of ≤ 2.5 × institutional upper limit of normal (ULN).
(2) Total serum bilirubin level of ≤ 1.5 × institutional ULN.
(3) Serum creatinine level of ≤ 1.5 × institutional ULN or an estimated glomerular filtration rate (eGFR) of > 50 mL/min.
4. Subject is suitable for oral administration of ASP2215.
5. Female subject falls under the following:
(1) Of non-childbearing potential:
(2) Post-menopausal (defined as at least 1 year with no menses without a medical reason such as drug administration) at screening, or
(3) Documented surgically sterile or status post-hysterectomy (at least 1 month prior to screening)
(4) Of childbearing potential:
(5) Has a negative result for the pregnancy test at screening, and,
(6) Agrees to use an appropriate contraception starting at screening and throughout the study period and for 60 days after the final study drug administration.
6. Female subject agrees not to breastfeed starting at screening and throughout the study period and for 60 days after the final study drug administration.
7. Female subject agrees not to donate ova starting at screening and throughout the study period and for 60 days after the final study drug administration.
8. Male subject and his female spouse/partner who is of childbearing potential agrees to use an appropriate contraception starting at screening and throughout the study period and for 120 days after the final study drug administration.
9. Male subject agrees not to donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
10. Subject agrees not to participate in another interventional study while on study treatment.
11. Subject can be admitted during the induction period.
[Phase 2 part]
1. Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) according to World Health Organization (WHO) classification (2017) documented within 28 days prior to enrollment.
2. Subject is positive for FLT3-ITD and/or TKD mutation in bone marrow or whole blood as determined by the central lab. Registration by the local lab result is not acceptable.
3. Subject has an ECOG performance status (PS) 0 to 1. Subject who has an ECOG PS 2 is eligible only if the primary disease related symptoms such as pneumonia and febrile neutropenia are the cause of PS score.
4. Subject is suitable for oral administration of ASP2215.
5. Female subject is not pregnant and at least 1 of the following conditions apply:
(1) Not a woman of childbearing potential (WOCBP)
(2) WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 180 days after final study treatment administration.
6. Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 60 days after the final study drug administration.
7. Female subject must not donate ova starting at screening and throughout the study period, and for 180 days after the final study drug administration.
8. Male subject and their female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards in addition to a barrier method starting at screening and continue throughout the study period and for 120 days after the final study drug administration.
9. Male subject must not donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
10. Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 120 days after the final study treatment administration.
11. Subject agrees not to participate in another interventional study while on treatment.
12. Subject must meet the following criteria as indicated on the clinical laboratory tests:
(1) Serum creatinine ≤ 1.5 × institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 50 mL/min/1.73m^2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation.
(2) Serum total bilirubin ≤ 2.5 mg/dL (43 μmol/L), except for subjects with Gilbert's syndrome.
(3) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN. If liver abnormality by the primary disease is suspected, subject may be pre-registered to initiate the chemotherapy. Prior to registration, AST/ALT values must meet the criteria to continue the study.
(4) Serum magnesium ≥ institutional lower limit of normal (LLN). Subject may pre-register without magnesium value, but subject must meet the criteria prior to the full registration on Day 8.
(5) Serum potassium ≥ institutional lower limit of normal (LLN).
1. Subject is defined as having previously untreated de novo AML according to the World Health Organization (WHO) criteria (2008) within 28 days prior to study enrollment.
2. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
3. Subject must meet all of the following criteria in the laboratory test at screening:
(1) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of ≤ 2.5 × institutional upper limit of normal (ULN).
(2) Total serum bilirubin level of ≤ 1.5 × institutional ULN.
(3) Serum creatinine level of ≤ 1.5 × institutional ULN or an estimated glomerular filtration rate (eGFR) of > 50 mL/min.
4. Subject is suitable for oral administration of ASP2215.
5. Female subject falls under the following:
(1) Of non-childbearing potential:
(2) Post-menopausal (defined as at least 1 year with no menses without a medical reason such as drug administration) at screening, or
(3) Documented surgically sterile or status post-hysterectomy (at least 1 month prior to screening)
(4) Of childbearing potential:
(5) Has a negative result for the pregnancy test at screening, and,
(6) Agrees to use an appropriate contraception starting at screening and throughout the study period and for 60 days after the final study drug administration.
6. Female subject agrees not to breastfeed starting at screening and throughout the study period and for 60 days after the final study drug administration.
7. Female subject agrees not to donate ova starting at screening and throughout the study period and for 60 days after the final study drug administration.
8. Male subject and his female spouse/partner who is of childbearing potential agrees to use an appropriate contraception starting at screening and throughout the study period and for 120 days after the final study drug administration.
9. Male subject agrees not to donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
10. Subject agrees not to participate in another interventional study while on study treatment.
11. Subject can be admitted during the induction period.
[Phase 2 part]
1. Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) according to World Health Organization (WHO) classification (2017) documented within 28 days prior to enrollment.
2. Subject is positive for FLT3-ITD and/or TKD mutation in bone marrow or whole blood as determined by the central lab. Registration by the local lab result is not acceptable.
3. Subject has an ECOG performance status (PS) 0 to 1. Subject who has an ECOG PS 2 is eligible only if the primary disease related symptoms such as pneumonia and febrile neutropenia are the cause of PS score.
4. Subject is suitable for oral administration of ASP2215.
5. Female subject is not pregnant and at least 1 of the following conditions apply:
(1) Not a woman of childbearing potential (WOCBP)
(2) WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 180 days after final study treatment administration.
6. Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 60 days after the final study drug administration.
7. Female subject must not donate ova starting at screening and throughout the study period, and for 180 days after the final study drug administration.
8. Male subject and their female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards in addition to a barrier method starting at screening and continue throughout the study period and for 120 days after the final study drug administration.
9. Male subject must not donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
10. Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 120 days after the final study treatment administration.
11. Subject agrees not to participate in another interventional study while on treatment.
12. Subject must meet the following criteria as indicated on the clinical laboratory tests:
(1) Serum creatinine ≤ 1.5 × institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 50 mL/min/1.73m^2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation.
(2) Serum total bilirubin ≤ 2.5 mg/dL (43 μmol/L), except for subjects with Gilbert's syndrome.
(3) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN. If liver abnormality by the primary disease is suspected, subject may be pre-registered to initiate the chemotherapy. Prior to registration, AST/ALT values must meet the criteria to continue the study.
(4) Serum magnesium ≥ institutional lower limit of normal (LLN). Subject may pre-register without magnesium value, but subject must meet the criteria prior to the full registration on Day 8.
(5) Serum potassium ≥ institutional lower limit of normal (LLN).
Exclusion Criteria
[Phase 1 part]
1. Subject was diagnosed with acute promyelocytic leukemia (APL).
2. Subject has breakpoint cluster region-abelson (BCR-ABL)-positive leukemia (chronic myelogenous leukemia in blast crisis).
3. Subject has active malignant tumors other than AML or myelodysplastic syndrome (MDS).
4. Subject has received prior AML treatment except for the following:
(1) Urgent leukapheresis
(2) Hydroxyurea administration for emergency treatment of hyperleukocytosis (≤ 7 days)
(3) Administration of retinoic acid before the diagnosis to exclude APL (≤ 7 days)
(4) Supportive care using growth factors or cytokines
(5) Steroid administration to treat hypersensitivity or blood transfusion reactions
5. Subject has clinically active central nervous system leukemia.
6. Subject has disseminated intravascular coagulation (DIC).
7. Subject has had major surgery within 28 days prior to the first study drug administration.
8. Subject has had radiation therapy within 28 days prior to the first study drug administration.
9. Subject has congestive heart failure of New York Heart Association (NYHA) class 3 or 4, or subject with a past history of congestive heart failure of NYHA class 3 or 4 and in whom echocardiogram (ECHO) or Multiple Gate Acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of < 45%.
10. Subject has cardiac impairment or a clinically significant cardiac disease, including any one of the following:
(1) Complete left bundle branch block
(2) Obligate use of a cardiac pacemaker
(3) Long QT syndrome at Screening
(4) Prolongation of the QTc interval (> 450 ms) on electrocardiogram (ECG) at screening
(5) Right bundle branch block + left anterior hemiblock (bifascicular block)
(6) Angina pectoris within 3 months prior to study drug administration
(7) Acute myocardial infarction within 3 months prior to study drug administration
11. Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
12. Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
13. Subject requires treatment with concomitant drugs that target serotonin 5HT1 or 5HT2B receptors or sigma receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject.
14. Subject has an active uncontrollable infection.
15. Subject is known to have human immunodeficiency virus (HIV) infection.
16. Subject has active hepatitis B or C or other active hepatic disorders.
17. Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation.
18. Potassium and magnesium levels of below institutional lower limit of normal in the laboratory test at screening.
[Phase 2 part]
1. Subject was diagnosed with acute promyelocytic leukemia (APL).
2. Subject has known BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
3. Subject has therapy-related AML.
4. Subject has active malignant tumors other than AML.
5. Subject has received previous therapy for AML, with the exception of the following:
(1) Emergency leukapheresis
(2) Emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 10 days
(3) Preemptive treatment with retinoic acid prior to exclusion of APL ≤ 7 days
(4) Growth factor or cytokine support
(5) Steroids for the treatment of hypersensitivity or transfusion reactions.
6. Subject has QTcF interval > 450 ms (average of triplicate determinations based on central reading).
7. Subject with long QT syndrome.
8. Subject has clinically active central nervous system leukemia.
9. Subject has had major surgery within 4 weeks prior to the first study dose.
10. Subject has radiation therapy within 4 weeks prior to the first study dose.
11. Subject has immediate life-threatening, severe complications of leukemia such as severe uncontrolled bleeding and/or severe disseminated intravascular coagulation
12. Subject is known to have human immunodeficiency virus infection.
13. Subject has active hepatitis B or C.
14. Subject has an uncontrolled infection. An infection controlled with an approved or closely monitored antibiotic/antiviral/antifungal treatment is allowed.
15. Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart failure of NYHA class 3 or 4 and echocardiogram (ECHO) or Multiple Gate Acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of < 45%.
16. Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A.
17. Subject requires treatment with concomitant drugs that target serotonin 5HT2B receptors or sigma nonspecific receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject.
18. Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
19. Subject has prior malignancies, except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed.
20. Subject has any condition which makes the subject unsuitable for study participation.
1. Subject was diagnosed with acute promyelocytic leukemia (APL).
2. Subject has breakpoint cluster region-abelson (BCR-ABL)-positive leukemia (chronic myelogenous leukemia in blast crisis).
3. Subject has active malignant tumors other than AML or myelodysplastic syndrome (MDS).
4. Subject has received prior AML treatment except for the following:
(1) Urgent leukapheresis
(2) Hydroxyurea administration for emergency treatment of hyperleukocytosis (≤ 7 days)
(3) Administration of retinoic acid before the diagnosis to exclude APL (≤ 7 days)
(4) Supportive care using growth factors or cytokines
(5) Steroid administration to treat hypersensitivity or blood transfusion reactions
5. Subject has clinically active central nervous system leukemia.
6. Subject has disseminated intravascular coagulation (DIC).
7. Subject has had major surgery within 28 days prior to the first study drug administration.
8. Subject has had radiation therapy within 28 days prior to the first study drug administration.
9. Subject has congestive heart failure of New York Heart Association (NYHA) class 3 or 4, or subject with a past history of congestive heart failure of NYHA class 3 or 4 and in whom echocardiogram (ECHO) or Multiple Gate Acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of < 45%.
10. Subject has cardiac impairment or a clinically significant cardiac disease, including any one of the following:
(1) Complete left bundle branch block
(2) Obligate use of a cardiac pacemaker
(3) Long QT syndrome at Screening
(4) Prolongation of the QTc interval (> 450 ms) on electrocardiogram (ECG) at screening
(5) Right bundle branch block + left anterior hemiblock (bifascicular block)
(6) Angina pectoris within 3 months prior to study drug administration
(7) Acute myocardial infarction within 3 months prior to study drug administration
11. Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
12. Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
13. Subject requires treatment with concomitant drugs that target serotonin 5HT1 or 5HT2B receptors or sigma receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject.
14. Subject has an active uncontrollable infection.
15. Subject is known to have human immunodeficiency virus (HIV) infection.
16. Subject has active hepatitis B or C or other active hepatic disorders.
17. Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation.
18. Potassium and magnesium levels of below institutional lower limit of normal in the laboratory test at screening.
[Phase 2 part]
1. Subject was diagnosed with acute promyelocytic leukemia (APL).
2. Subject has known BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
3. Subject has therapy-related AML.
4. Subject has active malignant tumors other than AML.
5. Subject has received previous therapy for AML, with the exception of the following:
(1) Emergency leukapheresis
(2) Emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 10 days
(3) Preemptive treatment with retinoic acid prior to exclusion of APL ≤ 7 days
(4) Growth factor or cytokine support
(5) Steroids for the treatment of hypersensitivity or transfusion reactions.
6. Subject has QTcF interval > 450 ms (average of triplicate determinations based on central reading).
7. Subject with long QT syndrome.
8. Subject has clinically active central nervous system leukemia.
9. Subject has had major surgery within 4 weeks prior to the first study dose.
10. Subject has radiation therapy within 4 weeks prior to the first study dose.
11. Subject has immediate life-threatening, severe complications of leukemia such as severe uncontrolled bleeding and/or severe disseminated intravascular coagulation
12. Subject is known to have human immunodeficiency virus infection.
13. Subject has active hepatitis B or C.
14. Subject has an uncontrolled infection. An infection controlled with an approved or closely monitored antibiotic/antiviral/antifungal treatment is allowed.
15. Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart failure of NYHA class 3 or 4 and echocardiogram (ECHO) or Multiple Gate Acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of < 45%.
16. Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A.
17. Subject requires treatment with concomitant drugs that target serotonin 5HT2B receptors or sigma nonspecific receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject.
18. Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
19. Subject has prior malignancies, except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed.
20. Subject has any condition which makes the subject unsuitable for study participation.
The Estimated Number of Participants
-
Taiwan
8 participants
-
Global
80 participants
